Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Circulation

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.cir.100.6.685PMID 9808602
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prospective study of a self-report type A scale and risk of coronary heart disease: test of the MMPI-2 type A scale.

  1999cited by this paper
• Estimation of oxygen delivery in newborns with a univentricular circulation.

  1998cited by this paper
• Effects of losartan on hypertension and left ventricular mass: a long-term study

  1998cited by this paper
• Anxiety and coronary heart disease: A synthesis of epidemiological, psychological, and experimental evidence

  1998cited by this paper
• Five-year follow-up for adverse outcomes in males with at least minimally positive angiograms: importance of "denial" in assessing psychosocial risk factors.

  1998cited by this paper
• Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension

  1998cited by this paper
• Do antihypertensive drugs differ in their ability to regress left ventricular hypertrophy?

  1997cited by this paper
• Accuracy and reproducibility of biplane two-dimensional echocardiographic measurements of left ventricular dimensions and function.

  1997cited by this paper
• Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

  1997cited by this paper
• Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors.

  1997cited by this paper
• Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

  1997cited by this paper
• The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.

  1997cited by this paper
• Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass.

  1997cited by this paper
• Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation.

  1997cited by this paper
• Increased left-ventricular mass after losartan treatment.

  1997cited by this paper
• H35: Baseline characteristics of the life (Losartan intervention for endpoint reduction) in hypertension study

  1997cited by this paper
• Do antihypertensive drugs differ in their ability to regress left ventricular hypertrophy

  1997cited by this paper
• Angiotensin receptors and their antagonists.

  1996cited by this paper
• Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine

  1996cited by this paper
• Left ventricular wall stress and sarcoplasmic reticulum Ca(2+)-ATPase gene expression in renal hypertensive rats: dose-dependent effects of ACE inhibition and AT1-receptor blockade.

  1996cited by this paper
• A prospective study of anger and coronary heart disease. The Normative Aging Study.

  1996cited by this paper
• Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies.

  1996cited by this paper
• Prognostic value of left ventricular mass and geometry in systemic hypertension with left ventricular hypertrophy.

  1996cited by this paper
• Denial of Depression as an Independent Correlate of Coronary Artery Disease

  1996cited by this paper
• Localization of the angiotensin II receptor subtypes in the human atrium.

  1996influential reference
• Long-term effects of losartan on blood pressure and left ventricular structure in essential hypertension.

  1996cited by this paper
• Influence of isradipine and spirapril on left ventricular hypertrophy and resistance arteries.

  1996cited by this paper
• Left ventricular mass and function in primary hypertension.

  1996cited by this paper
• Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review.

  1995cited by this paper
• Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS).

  1995cited by this paper
• Sex, age, and disease affect echocardiographic left ventricular mass and systolic function in the free-living elderly. The Cardiovascular Health Study.

  1995cited by this paper
• ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study on behalf of the RACE study group.

  1995cited by this paper
• Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment

  1995cited by this paper
• ACE inhibitor ramipril is more effective than the β-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study

  1995cited by this paper
• Losartan in essential hypertension: Effects on blood pressure and left ventricular maass

  1995cited by this paper
• Criteria for an informative trial of left ventricular hypertrophy regression.

  1994cited by this paper
• Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy.

  1994cited by this paper
• Usefulness of intermittent monitoring of mixed venous oxygen saturation after stage I palliation for hypoplastic left heart syndrome.

  1994cited by this paper
• Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro.

  1994cited by this paper
• Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone.

  1994cited by this paper
• Balancing the circulation: theoretic optimization of pulmonary/systemic flow ratio in hypoplastic left heart syndrome.

  1994cited by this paper
• Quantifying the density of Friedman's pathogenic emotions (AIAI).

  1993cited by this paper
• Molecular characterization of angiotensin II--induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype.

  1993influential reference
• Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1‐receptor subtype

  1993cited by this paper
• Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies.

  1992cited by this paper
• Regression of left ventricular hypertrophy in previously untreated essential hypertension: different effects of enalapril and hydrochlorothiazide

  1992cited by this paper
• Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study.

  1990cited by this paper
• Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study.

  1990cited by this paper
• Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart.

  1990cited by this paper
• Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings.

  1986influential reference
• Recommendations Regarding Quantitation in M-Mode Echocardiography: Results of a Survey of Echocardiographic Measurements

  1978influential reference

• Prevention and treatment of hypertensive left ventricular hypertrophy

  2024cites this paper
• Big Data in multiscale modelling: from medical image processing to personalized models

  2023cites this paper
• SILICOFCM platform, multiscale modeling of left ventricle from echocardiographic images and drug influence for cardiomyopathy disease

  2022cites this paper
• Comparative efficacy of different types of antihypertensive drugs in reversing left ventricular hypertrophy as determined with echocardiography in hypertensive patients: A network meta‐analysis of randomized controlled trials

  2020cites this paper
• The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings

  2020cites this paper
• Changes in left ventricular geometry during antihypertensive treatment

  2018cites this paper
• Bisoprolol Reduced Left Ventricular Hypertrophy in Hypertensive Patients with Gln27Gln (wildtype) ?2-Adrenergic Receptor Receiving Angiotensin II Receptor Blocker (ARB)

  2017cites this paper
• Prognostičko značenje hipertrofije lijeve klijetke u kardiovaskularnom kontinuumu

  2017cites this paper
• Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial).

  2017cites this paper
• Modulation of cardiac function by oxidized type I protein kinase A

  2017cites this paper
• Antihypertensive Therapies and Left Ventricular Hypertrophy

  2017cites this paper
• Left ventricular hypertrophy in arterial hypertension as an indicator of cardiovascular risk and the the goal for antihypertensive therapy

  2016cites this paper
• Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease.

  2016cites this paper
• Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.

  2016cites this paper
• Association between coronary artery calcification and left ventricular diastolic dysfunction in elderly people

  2016cites this paper
• Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Diabetes Mellitus: Action to Control Cardiovascular Risk in Diabetes Blood Pressure Trial.

  2015cites this paper
• Distinguishing Hypertension From Hypertrophic Cardiomyopathy as a Cause of Left Ventricular Hypertrophy

  2015cites this paper
• Determinants of medium-term blood pressure variability and the related risks of stroke and dementia

  2014cites this paper
• Comparison of effects of nebivolol, carvedilol and irbesartan on left ventricular hypertrophy associated with hypertension.

  2014cites this paper
• Guidelines for the management of arterial hypertension

  2014cites this paper
• Efeito do treinamento aeróbio nas alterações sequenciais do miocárdio de SHR jovens: participação do sistema renina-angiotensina.

  2014cites this paper
• Inactivation of At1A Receptors Attenuate Lactate Accumulation and Improve Cardiac Performance and Acid-Base Homeostasis during Endurance Exercise

  2014cites this paper
• Diastolic blood pressure reduction contributes more to the regression of left ventricular hypertrophy: a meta-analysis of randomized controlled trials

  2013cites this paper
• Diminazene Aceturate Enhances Angiotensin-Converting Enzyme 2 Activity and Attenuates Ischemia-Induced Cardiac Pathophysiology

  2013cites this paper
• A 26-week repeated-dose toxicity study of allisartan isoproxil in Sprague-Dawley rats

  2013cites this paper
• Effects of ACE-inhibitors and angiotensin receptor blockers on inflammation.

  2012cites this paper
• Ultrasound and radiology surrogate endpoints in pharmacological studies.

  2012cites this paper
• Effects of the combinations of amlodipine/valsartan versus losartan/hydrochlorothiazide on left ventricular hypertrophy as determined with magnetic resonance imaging in patients with hypertension

  2011cites this paper
• Effects of the Angiotensin II Receptor Blocker (Candesartan) on Anthracycline-induced Cardiotoxicity

  2011cites this paper
• Valsartan plus hydrochlorothiazide: a review of its use since its introduction

  2011influential citation
• [Application of AT1-angiotensin II receptor blocker valsartan in clinical practice].

  2011cites this paper
• The treatment of cardiovascular disease continuum: focus on prevention and RAS blockade.

  2010cites this paper
• Effect of candesartan treatment on left ventricular remodeling after aortic valve replacement for aortic stenosis.

  2010cites this paper
• Role of the Renin-Angiotensin System in Cardiovascular Disease

  2010cites this paper
• Stopping the cardiovascular disease continuum: Focus on prevention.

  2010cites this paper
• Comparing angiotensin II receptor blockers on benefits beyond blood pressure

  2010cites this paper
• Regression of Left Ventricular Mass by Antihypertensive Treatment: A Meta-Analysis of Randomized Comparative Studies

  2009cites this paper
• Inhibiting the renin–angiotensin system: Why and in which patients

  2009cites this paper
• The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study.

  2009cites this paper
• Beta-blockers in the treatment of hypertension: latest data and opinions.

  2008cites this paper
• Heart failure with preserved ejection fraction: hypertension, diabetes, obesity/sleep apnea, and hypertrophic and infiltrative cardiomyopathy.

  2008cites this paper
• Salacia oblonga root decreases cardiac hypertrophy in Zucker diabetic fatty rats: inhibition of cardiac expression of angiotensin II type 1 receptor

  2008cites this paper
• Evidence for benefits of angiotensin receptor blockade beyond blood pressure control

  2008cites this paper
• Angiotensin II receptor blockers in the treatment of the cardiovascular disease continuum.

  2008cites this paper
• Establishing a new option for target-organ protection: rationale for ARB plus ACE inhibitor combination therapy.

  2008cites this paper
• Studies on left ventricular hypertrophy regression in arterial hypertension: a clear message for the clinician?

  2008cites this paper
• 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

  2007cites this paper
• Role of Angiotensin-Receptor Blockers in the Prevention of Cardiovascular Risk: Clinical Guidelines

  2007cites this paper
• [ESH/ESC 2007 Guidelines for the management of arterial hypertension].

  2007cites this paper
• 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)

  2007cites this paper
• HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo‐controlled pilot study

  2007cites this paper
• 2007 ESH‐ESC Guidelines for the management of arterial hypertension

  2007cites this paper
• 2007 Guidelines for the Management of Arterial Hypertension The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European

  2007cites this paper
• Moexipril and left ventricular hypertrophy

  2007cites this paper
• Valsartan/hydrochlorothiazide: a review of its use in the management of hypertension.

  2006cites this paper
• Prospects for the prevention of stroke

  2006cites this paper
• THE ROLE OF ANGIOTENSIN-(1-7) IN CARDIOVASCULAR PHYSIOLOGY

  2006cites this paper
• Regression of left ventricular hypertrophy by a candesartan-based regimen in clinical practice The VIPE study

  2006cites this paper
• Rationale and design: the VALsartan In Diastolic Dysfunction (VALIDD) Trial: evolving the management of diastolic dysfunction in hypertension.

  2006cites this paper
• Impact of baseline echocardiography on treatment outcome in primary care patients with newly detected arterial hypertension: a randomized trial.

  2006cites this paper
• Blockade of angiotensin II type 1 receptor improves the arrhythmia morbidity in mice with left ventricular hypertrophy.

  2006cites this paper
• Clinical experience with the use of angiotensin receptor blockers in patients with cardiovascular, cerebrovascular and renal diseases.

  2006cites this paper
• Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension.

  2006cites this paper
• Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension.

  2006cites this paper
• Clinical Evidence for the Cardiovascular Benefits of Angiotensin Receptor Blockers

  2006cites this paper
• Efficacy of Irbesartan on Left Ventricular Mass and Arterial Stiffness in Hypertensive Patients

  2006cites this paper
• Clinical Evidence for the Cardiovascular Benefits of Angiotensin Receptor Blockers

  2006cites this paper
• Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study.

  2005cites this paper
• Effect of Losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy.

  2005cites this paper
• Effect of 24-Week Treatment with Telmisartan on Myocardial Structure and Function: Relationship to Insertion/Deletion Polymorphism of the Angiotensin-Converting Enzyme Gene

  2005cites this paper
• Induction of Cardiac Hypertrophy by a Controlled Reproducible Sutureless Aortocaval Shunt in the Mouse

  2005cites this paper
• Targeting the renin-angiotensin-aldosterone-system in atrial fibrillation: a shift from electrical to structural therapy?

  2005cites this paper
• Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan

  2005cites this paper
• Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone

  2005cites this paper
• Irbesartan and atenolol improve diastolic function in patients with hypertensive left ventricular hypertrophy

  2005cites this paper
• Cardiac structural and functional changes during long-term antihypertensive treatment with lacidipine and atenolol in the European Lacidipine Study on Atherosclerosis (ELSA)

  2005cites this paper
• Valsartan Abolishes Most of the Memory-Improving Effects of Intracerebroventricular Angiotensin II in Rats

  2005cites this paper
• Pathophysiology and treatment of hypertensive left ventricular hypertrophy

  2005cites this paper
• Early Target Organ Damage and Its Reversibility: The Heart

  2004cites this paper
• Surrogate markers for cardiovascular disease: structural markers.

  2004cites this paper
• Renin-Angiotensin System and Angiotensin Receptor Blockers in the Metabolic Syndrome

  2004cites this paper
• Candesartan, an angiotensin II receptor blocker, improves left ventricular hypertrophy and insulin resistance.

  2004cites this paper
• Odporúčania Európskej hypertenziologickej spoločnosti a Európskej kardiologickej spoločnosti pre rok 2003 v manažmente artériovej hypertenzie

  2004cites this paper
• Prevention of Cardiac Hypertrophy by Angiotensin II Type-2 Receptor Gene Transfer

  2004cites this paper
• The effect of valsartan on regression of left ventricular hypertrophy in type 2 diabetic patients

  2004cites this paper
• Managing High‐Risk Patients With Hypertension: Focus on the Renin‐Angiotensin System

  2004cites this paper
• Transforming growth factor beta1 genotype and change in left ventricular mass during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).

  2004cites this paper
• Safety of Telmisartan in Patients with Arterial Hypertension

  2004cites this paper
• Effects of losartan and valsartan on left ventricular hypertrophy and function in essential hypertension

  2004cites this paper
• AII antagonists in hypertension, heart failure, and diabetic nephropathy: focus on losartan

  2004cites this paper
• Plasma B-type natriuretic peptide reflects left ventricular hypertrophy and diastolic function in hypertension.

  2004cites this paper
• [Pharmaco-economical aspects of reduction of left ventricular hypertrophy in hypertensive patients: how we can use the results of clinical trials].

  2004cites this paper
• Angiotensin receptor blockade in the challenging era of systolic hypertension

  2004cites this paper
• Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy.

  2004cites this paper
• Regression of left ventricular hypertrophy and improvement of diastolic function in hypertensive patients treated with telmisartan.

  2004cites this paper
• Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both.

  2004cites this paper
• Clinical Experience With Angiotensin Receptor Blockers With Particular Reference to Valsartan

  2004cites this paper
• Effect of Irbesartan Versus Atenolol on Left Ventricular Mass and Voltage: Results of the CardioVascular Irbesartan Project

  2004cites this paper
• Angiotensin II receptor blockers in older patients.

  2004cites this paper
• AT1 Receptor Antagonists: Pharmacology

  2004cites this paper